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A diagnosis of motor Parkinson’s disease (PD) is preceded by a prolonged premotor phase
with accumulating neuronal damage. Here we examined the temporal relation between α-
synuclein (α-syn) T cell reactivity and PD. A longitudinal case study revealed that elevated α-
syn-specific T cell responses were detected prior to the diagnosis of motor PD, and declined
after. The relationship between T cell reactivity and early PD in two independent cohorts
showed that α-syn-specific T cell responses were highest shortly after diagnosis of motor PD
and then decreased. Additional analysis revealed significant association of α-syn-specific T
cell responses with age and lower levodopa equivalent dose. These results confirm the
presence of α-syn-reactive T cells in PD and show that they are most abundant immediately
after diagnosis of motor PD. These cells may be present years before the diagnosis of motor
PD, suggesting avenues of investigation into PD pathogenesis and potential early diagnosis.
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Parkinson’s disease (PD) is a complex disease with severalphases: a preclinical phase that may include physiological orpathological changes, but no symptoms; a prodromal phase
that includes non-motor symptoms such as constipation, REM
sleep behavior disorder, and hyposmia1; and motor PD char-
acterized by the cardinal features of tremor, rigidity, bradykinesia,
and postural imbalance. The presence of these motor features
allows clinical diagnosis of PD.
The motor symptoms of PD are primarily due to the loss of
dopaminergic neurons of the substantia nigra pars reticulata
(SNpc)2. In postmortem brain, loss of dopaminergic neurons can
be detected by stereological analysis and labeling of the dopamine
synthetic enzyme tyrosine hydroxylase3. A stereological analysis of
20 brains from subjects who died from 1 to 27 years after PD
diagnosis indicates that the number of SNpc neurons is decreased
by 50–90% during the first four years following diagnosis3; while
after this period, the number of labeled neurons remains fairly
constant. Similarly, the number of neuromelanin-pigmented SNpc
cells from the same subjects at 3 to 7 years post diagnosis shows a
decrease of 33–80% relative to controls. By 4 years after diagnosis
of motor PD, the markers of dopamine axons in the dorsal
putamen are virtually absent. These observations are consistent
with a premotor phase during which there is extensive damage to
SNpc neurons preceding the motor symptoms that typically lead
to diagnosis and the identification of clinical disease1.
The concept of an extensive prodromal phase of PD is further
supported by the very common occurrence of symptoms that pre-
cede the diagnosis of motor PD, including hyposmia, constipation,
mood changes, and REM sleep behavior disorder1. Although these
symptoms can precede PD diagnosis by decades, their presence is
not sufficient to diagnose PD and, although sensitivity is relatively
good, the specificity is poor for most subjects4. These prodromal
non-motor features often associated with PD are thought to be due
to the loss of additional catecholaminergic and cholinergic neurons
and other pathological changes outside the SNpc5.
Attempts to develop treatment to slow the progression of PD
have so far been unsuccessful. One of the important factors in the
lack of success is that it may be difficult to modify the disease
when treatment is initiated after the majority of SNpc neurons
have already been lost. Thus, identifying effective early predictors
of PD is of fundamental importance to developing future thera-
pies6. One approach to develop early prediction is to identify
additional features associated with the preclinical or prodromal
phases of PD, including potential inflammatory manifestations7,8.
A recent study by our team found that some PD patients
possess T cells that recognize specific epitopes derived from the
PD-associated protein, α-synuclein (α-syn)9, indicating the pre-
sence of autoimmune features in this disease. Classical auto-
immune disorders such as diabetes mellitus type I are well
established to display differences in specific T cell types over the
course of the disease10. Here, we present an analysis of α-syn-
specific T cells in two ways: (1) by examining a case study of a
single individual with blood samples from many years prior to
and during the course of motor PD, and (2) by investigating α-
syn-specific T cells in two cohorts of PD patients and age-
matched non-PD controls. We detected α-syn-specific T cells in
the single case years before clinical diagnosis of motor PD, and a
higher abundance of pro-inflammatory T cells in a cross-sectional
PD patient population shortly after diagnosis of motor PD. These
findings indicate that specific T cell reactivity to α-syn-derived
epitopes is a feature of premotor and early motor PD.
Results
A case study of α-syn-specific T cell reactivity. We were con-
tacted by an individual who was diagnosed with motor PD in
2009 but was otherwise healthy, and who had for unrelated
reasons cryopreserved peripheral blood mononuclear cell
(PBMC) samples available that were collected from 1998 to
present. The individual had read our previous study9 and gen-
erously donated the previously collected samples for analysis. As
in the previous study, PBMCs were stimulated for 14 days in vitro
with an α-syn epitope pool (a total of 12 peptides). After 2 weeks,
cultures were harvested and stimulated with antigen or PHA, as a
control, in a triple-color IFNγ, IL-5, and IL-10 Fluorospot assay.
As before, IFNγ was examined as a representative cytokine for
CD4+ Th1 cells and CD8+ T cells, while IL-5/IL-4 (in flow
cytometry assays) was examined to indicate CD4+ Th2 T cells,
and, in addition, IL-10 was analyzed as representative of potential
regulatory cells.
We detected α-syn-specific T cell reactivity that was deconvo-
luted and mapped to the α-syn61-75EQVTNVGGAVVTGVT
peptide in samples from 2005, 2006, and 2015 (Fig. 1a and
Supplementary Fig. 1). Since we had access to the HLA type of the
donor, we were able to predict HLA binding of this particular
peptide to each of the expressed alleles. The EQVTNVG-
GAVVTGVT peptide was predicted to bind with high affinity
(71 nM) to the HLA DRB1*01:01 allele expressed by the donor
(HLA type of case study donor: DRB1*01:01/*03:01, DRB3*01:01,
DQB1*02:01/*05:01, DQA1*01:01/*05:01; DPB1*04:01/*04:01).
The α-syn-specific response was further characterized by ICS
assays in samples collected between 1998 and 2015, which
revealed that the response was mediated by CD4+ T cells for both
IFNγ and IL-4 (Fig. 1b, c). No α-syn-specific IL-10 production was
detected in the ICS assay (Fig. 1d).
We then analyzed the evolution of the α-syn-specific and
globally stimulated (PHA control) T cell reactivity. Notably,
strong T cell reactivity against α-syn was detected between the
years 1998 and 2006, more than a decade before the onset of
motor PD symptoms and clinical diagnosis. No samples were
analyzed for reactivity between the onset of motor PD symptoms
and clinical diagnosis. Significant variability in α-syn-specific
responses was observed between 2006 and 2008, including in the
positive PHA controls, during which the donor experienced
shingles (herpes zoster). Interestingly, the α-syn-specific reactivity
detected after diagnosis (2012–2018) was significantly lower than
between 1998 and 2006 (Fig. 1e). Overall, there was a significant
difference in α-syn-specific T cell reactivity comparing pre- and
post-PD onset/diagnosis, while no significant difference was
observed for the PHA control (Fig. 1f).
Taken together, this case study revealed strong CD4+ T cell
responses against the EQVTNVGGAVVTGVT α-syn epitope.
The reactivity was detectable 10 years before onset and diagnosis
of motor PD, and was associated with a wide variation in
response magnitude. Higher responses were detected before
onset/diagnosis, leading us to design a broader study of T cell
responses over the course of PD.
Preferential α-syn-specific T cell reactivity in PD. Previously
reported α-syn-specific T cell reactivity was determined in a
cohort of individuals recruited by the Columbia University
Medical Center (CUMC) and the La Jolla Institute for Immu-
nology (LJI). Here, we enrolled additional donors from RUMC,
UCSD, and University of Alabama at Birmingham (UAB) (see
“Material and methods”). We determined the α-syn-specific T cell
reactivity in PD patients and healthy age-matched controls (HC)
from these sites. As before, PBMCs were stimulated for 14 days
with an α-syn epitope pool derived from the previous study9, and
IFNγ, IL-5, and IL-10 responses against the epitope pool were
measured in IFNγ, IL-5, and IL-10 Fluorospot assays after the
in vitro culture. If cell numbers allowed, positive pools were
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deconvoluted to identify the specific peptides that elicited cyto-
kine responses. We previously reported higher α-syn-specific
reactivity in PD compared with HC, when comparing the mag-
nitude of response against peptide and participant combinations9.
The present results in this heterogenous population against the 11
different epitopes deconvoluted after in vitro stimulation con-
firmed significantly higher magnitude of responses in PD than
HC (p < 0.0001, Supplementary Fig. 2).
Subsequent analysis focused on responses to the peptide pool
with 11 α-syn-derived epitopes; deconvolution of all peptides
could not be consistently performed due to limited cell numbers.
Comparison of IFNγ, IL-5, and IL-10 production between the two
cohorts on a per donor basis revealed no differences when IL-5
and IFNγ were considered separately (Fig. 2a, b), and a significant
difference when the IL-10 responses were considered (p= 0.04,
Fig. 2c). When the overall sum of responses was compared
between PD and HC, there were significantly higher overall
responses when an arbitrary threshold of 250 SFC was considered
(p= 0.02; Fisher’s exact test, Fig. 2d).
To determine whether the higher α-syn-specific T cell
responses in individuals with PD compared with HC occurs in
other neurodegenerative diseases, we determined the α-syn-
specific T cell reactivity in Alzheimer’s disease (AD) patients and
HC (Materials and methods). There was no difference in
reactivity between these cohorts (p= 0.15; two-tailed
Mann–Whitney test, and p= 0.21; Fisher’s exact test with a
threshold of 250 SFC, Fig. 2e). We further compared the HC from
the PD study to the HC from the AD study, as well as the PD and
AD cohorts. No differences were observed by the Fisher’s exact
test at a threshold of 250 SFC (p= 0.102 for HC in PD vs. HC in
AD, and p= 0.196 for PD vs. AD).
T cell reactivity is associated with early time points. To gain
further insight into the relation between disease pathogenesis and
T cell reactivity, we examined whether the T cell response in a
cross-sectional cohort was correlated with time from diagnosis of
motor PD. We found that the reactivity was higher closer to PD
diagnosis and then waned (Fig. 3a).
a b c d
e f
Fig. 1 α-Syn-specific T cell responses in a longitudinal case study of PD. a Total magnitude of response expressed as total SFC (sum of IFNγ, IL-5, and
IL-10 responses) per 106 cultured PBMC against a pool of α-syn peptides (furthest to the right) and all individual α-syn peptides included in the pool.
Representative data from PBMC collected in 2006. b–d After eliminating non-lymphocytes and doublet cells by forward and side-scatter, and dead cells by
Live/Dead stain, CD3+ T cells were gated based on their CD4 and CD8 expression (CD8+, CD8+CD4+, CD4+, CD8−CD4−), and other populations as
indicated; CD3−CD19− and CD19+ (Supplementary Fig. 5), percentage cytokine of live cells from each of these were plotted. b IFNγ (n= 6), c IL-4 (n = 6),
and d IL-10 (n= 3). Each point represents a sample collected between 1998 and 2015 (1998, 2005, 2006, 2007, 2013, and 2015); median ± interquartile
range is indicated. e Total magnitude of response expressed as total SFC (sum of IFNγ, IL-5, and IL-10 responses) per 106 cultured PBMC against a pool of
α-syn peptides or PHA. The time period spans 1998 (pre-2001) to 2018. Median ± interquartile range is indicative of individual experimental replicates.
Pre- March-01 n= 10, Oct-05 n= 4, Jul-06 n= 3, Mar-07 n= 9, Apr-07 n= 3, May-07 n= 5, Oct-07 n= 1, Jan-13 n= 4, Aug-15 n= 12, and May-18 n= 2.
f Total magnitude of response divided into pre- (1998–2006) (n= 17) and (2007–2008) (n= 18), which reflects the period this individual experienced
shingles) and post- (2009–2018) (n= 18) PD onset/diagnosis for α-syn-specific responses (left) and PHA (right). Each point represents an individual
independent experimental replicate; the median ± interquartile range is indicated. Two-tailed Mann–Whitney test. The data are displayed on a
logarithmic scale.
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To confirm the inverse correlation between time from
diagnosis and α-syn-specific reactivity, samples derived from a
new independent cohort of 20 PD patients, all recruited within 10
years of diagnosis, were analyzed. The results shown in Fig. 3b
confirm the previous finding of the reactivity being higher closer
to PD diagnosis.
When all the data were considered and plotted together
(Fig. 3c), the higher reactivity closer to PD diagnosis was evident.
Overall when the frequency of PD patients responding above an
arbitrary cut-off of 250 SFC was considered, 39.7% (29/73) of
donors diagnosed <10 years ago responded, whereas only 8.6% of
donors (3/23) with diagnosis >10 years ago exhibited a response
to α-syn (p= 0.022, Table 1).
T cell reactivity is linked to pro-inflammatory cytokines. Next,
we investigated in more detail the relationship between time since
diagnosis and IFNγ, IL-5, and IL-10 production. We found that
the trend for all cytokines was the same, with the reactivity being
higher closer to diagnosis (Fig. 4a–c).
We also calculated the frequency of response using the same
cut-offs as above: 250 SFC and 10 years of diagnosis (Table 1).
We found that, in the case of IFNγ, 26% (19/73) of patients
diagnosed <10 years ago responded as compared with 4.3% (1/23)
diagnosed >10 years ago (p= 0.036). In the case of IL-5 and IL-10,
15% (11/73) and 16.4% (12/73) of patients diagnosed <10 years
ago responded, respectively, while only 4.3% (1/23) of those
diagnosed >10 years ago responded, which corresponded to a
nonsignificant trend (p= 0.283 and 0.179) in the same direction
as observed for IFNγ. Overall, these data indicate a negative
(inverse) correlation between the number of years after disease
onset and T cell reactivity.
a b c d e
Fig. 2 Reactivity to α-syn in patients with PD or AD as compared with HC. Magnitude of responses a IFNγ, b IL-5, c IL-10, and d sum of IFNγ, IL-5, and
IL-10 against the α-syn peptide pool as SFC per 106 cultured PBMC. Each point represents one participant. Closed circles, patients with PD (n= 77); open
circles, controls (n= 69). One-tailed Mann–Whitney test. As many participants showed no response, numerous points are at the limit of detection (100
SFC). Median ± interquartile range is displayed, but note that median values are at the limit of detection. The top interquartile range is visible in d. e Sum of
IFNγ, IL-5, and IL-10 against the α-syn peptide pool as SFC per 106 cultured PBMC. Each point represents one participant. Gray circles, patients with AD
(n= 38); open circles, controls (n= 41). Two-tailed Mann–Whitney test. As many participants showed no response, numerous points are at the limit of
detection (100 SFC). Median ± interquartile range is plotted, but the median values are at the limit of detection. The top interquartile range is visible for HC.
a b c
Fig. 3 Correlation between T cell reactivity and time since diagnosis. a Cohort 1 (n= 76 PD patients from UCSD, RUMC, LJI, and UAB), b Cohort 2 (n=
20 PD patients from UAB), c Cohorts 1 and 2 combined (n= 96 PD patients). The Y-axis shows the magnitude of responses (sum of IFNγ, IL-5, and IL-10)
against the α-syn peptide pool as SFC per 106 cultured PBMC. The X-axis shows the years since PD diagnosis. Each point represents one donor. Because
many participants showed no response, there are overlapping points at the limit of detection (100 SFC). Two-tailed Fisher’s exact test.
Table 1 Number of responders and nonresponders at 250
SFC and 10-year diagnosis cut-off.
Cytokine (250
SFC cut-off)
Time since PD
diagnosis
Responders Nonresponders
Total (sum of
IFNγ, IL-5, IL-10)
<10 years 29 44
≥10 years 3 20
p value (Fisher’s exact) 0.022
IFNγ <10 years 19 54
≥10 years 1 22
p value (Fisher’s exact) 0.036
IL-5 <10 years 11 62
≥10 years 1 22
p value (Fisher’s exact) 0.283
IL-10 <10 years 12 61
≥10 years 1 22
p value (Fisher’s exact) 0.179
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In our previous study9, although IL-10 production was not
investigated in detail, the limited analysis we did indicated that
most of the α-syn-specific responses were mediated by CD4+
T cells with one CD8/class I restricted epitope also identified.
Here, to address the cell type associated with IL-10 production, 20
PD donors were stimulated in vitro with an α-syn epitope pool
for 2 weeks, and then the production of IFNγ, IL-4, and IL-10
along with the lineage-specific markers CD56, CD19, CD14, CD3,
CD4, and CD8 was analyzed by flow cytometry. The results
indicated that IFNγ and IL-4 were produced primarily by CD4+
T cells, while IL-10 is produced by both CD4+ and CD8+ T cells
(Fig. 5a–c), consistent with the previously reported data9. Boolean
gating of cytokine responses revealed that the majority of
responses were from unique T cells producing one of the three
cytokines, IFNγ, IL-4, or IL-10 (Fig. 5d), although some cells
produced both IFNγ and IL-4.
Because of their potential role in downregulating immune
responses, the phenotype of IL-10-producing T cells was
examined in more detail with particular attention to whether
they expressed markers associated with regulatory T cell (Treg)
populations, and conversely, whether Treg populations stimu-
lated with α-syn epitopes secreted IL-10. For this purpose, cells
were stained with CD3, CD4, CD8, CD127, and CD25 along with
IFNγ, IL-4, and IL-10 after 2-week in vitro stimulation assay. The
results demonstrated that IL-10 production was not associated
with expression of CD25+CD127lo Tregs, and conversely, that
CD25+CD127lo-expressing Tregs do not produce IL-10 in
response to the α-syn epitopes (Fig. 5e). Thus, a population of
CD25−CD127− T cells was responsible for the α-syn-specific
IL-10 response detected.
LED and age correlate with α-syn-specific T cell reactivity. We
next examined if the α-syn-specific T cell reactivity correlated
with clinical and patient-specific characteristics other than time
since diagnosis. We evaluated correlations of α-syn-specific T cell
reactivity with patient age, sex, and HLA type, as well as with
measurements of PD severity such as cognitive function (the
Montreal Cognitive Assessment (MoCA)11), motor examination
(Part III from the Unified Parkinson’s Disease Rating Scale
(UPDRS)12), and medication (levodopa equivalent dose; LED13)
scores. We found a positive correlation between age and T cell
reactivity to α-syn, with patients older than 70 years having more
frequent responses (p= 0.0177 Fisher’s exact test, Fig. 6a). No
correlations between age and T cell reactivity to α-syn were found
in HC (p= 0.51, Supplementary Fig. 3). We also noted a trend
toward correlation between T cell responses and sex (Fig. 6b).
Only 6 out of 26 (23%) female PD patients tested responded to
α-syn, as opposed to 27 out of 71 (38%) male patients, although
this difference was not significant (p= 0.2279, with male donors
showing a trend toward responding more vigorously than female
donors). These results are consistent with an overall increase of
autoimmunity with age14.
Our previous publication found an association with α-syn-
specific Y39 T cell responses and HLA DRB1*15:01 and
DRB5*01:019. Here, we compared the HLA alleles expressed by
PD patients to those expressed by HC to find HLA associations of
PD. We found that no HLA allele was associated with PD disease
after Bonferroni correction for multiple comparisons (Supple-
mentary Table 1). We also compared the HLA alleles of α-syn
responding individuals (either PD or HC with SFC > 250) to
nonresponders and found that no significant associations were
detected with α-syn responses (Supplementary Table 1).
We next examined potential correlations between T cell
reactivity and clinical variables by analyzing the scores for
MoCA, which measures cognitive dysfunction; UPDRS, which
measures motor and non-motor symptoms and follows the
longitudinal progress of PD; and LED, which is designed to
quantify anti-Parkinsonian medications. No significant correla-
tion was detected between T cell reactivity and cognitive or motor
scores, as MoCA (Fig. 6c) and UPDRS Part III (Fig. 6d) scores
were not associated with responses against α-syn. We obtained
the complete UPDRS scores (Parts I–IV) available from the
cohort recruited at UCSD (n= 33) and none of the subscales of
UPDRS were associated with responses against α-syn (Supple-
mentary Fig. 4). No association analysis was performed for
Hoehn & Yahr stages because 85% of the PD subjects were Stage
2, and only two individuals were rated as Stage 1 and a single
subject was rated as Stage 0, or for the Schwab and England
Activities of Daily Living scale, because 94% of the PD subjects
scored 80–100%. In contrast, our analyses revealed a significant
correlation between low LED (<1000 mg/day) and T cell
responses against α-syn (Fig. 6e). We reasoned that low LED
levels might be simply correlated with early motor disease.
Indeed, we found that, as expected, time from diagnosis and low
LED were positively correlated (Spearman r= 0.335, p= 0.0016)
(Fig. 6f). We next addressed whether these variables (low LED
and time from diagnosis) were independently correlated with α-
syn T cell reactivity. For this purpose, we segregated donors as a
function of these two variables. We found that responses were
essentially limited to donors that had both recent diagnosis and
low LED (Fig. 6g). A total of 25/28 responders (SFC > 250) were
diagnosed <10 years ago and had a LED score <1000 mg/day,
while 33/58 (SFC < 250) did not fit those criteria (p= 0.0029
Fisher’s exact test).
After noting the positive correlation between age and α-syn
responses, we found that a combination of low LED (<1000mg/day),
a b c
Fig. 4 Correlation between individual cytokine responses and time since diagnosis. Cohorts 1 and 2 combined (n= 96 PD patients). The Y-axis shows
the magnitude of responses a IFNγ, b IL-5, and c IL-10, against the α-syn peptide pool as SFC per 106 cultured PBMC. The X-axis shows the years since PD
diagnosis. Each point represents one donor. Because many participants showed no response, there are overlapping points at the limit of detection (100
SFC). The number of patients in each quadrant is indicated in each graph. Two-tailed Fisher’s exact test.
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time since diagnosis (<10 years), and age (≥70 years) formed an
optimum triad of parameters exhibiting maximum sensitivity and
specificity. Of the 22 PD donors that meet these three criteria, 15
responded to α-syn, resulting in 68% specificity (Fig. 6h). This
particular combination of the three clinical variables: low LED
(<1000 mg/day), time since diagnosis (<10 years), and age (≥70
years), captures 15 out of the 28 total PD donors that responded
to α-syn, indicating a 54% sensitivity (Fisher’s exact p= 0.0001,
Fig. 6h).
Discussion
Here we report that, in patients with motor PD, α-syn-specific T
cell responses are highest close to the time of motor PD diagnosis
and decline thereafter. These T cell responses are associated with
diverse immunological phenotypes, including both inflammatory
and potentially regulatory cytokine-secreting cells. We demon-
strate in a case study of a single individual in which T cells could
be analyzed over a decade that this α-syn-specific inflammatory T
cell response was present prior to onset of motor symptoms and
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Fig. 5 IFNγ, IL-4, and IL-10 are produced by distinct T cells in response to α-syn. a–d After eliminating non-lymphocytes/monocytes and doublet cells by
forward and side-scatter and dead cells by Live/Dead stain, cells were gated based on their cytokine expression and then cytokine-expressing cells were
gated based on their CD3+ and CD56+ expression. CD3+ T cells were gated based on their CD4 and CD8 expression (CD8+, CD8+CD4+, CD4+, CD8−
CD4−), and other populations based on CD3−CD56− and other markers as indicated; CD14−CD19+ (B cells), CD14+CD19− (Monocytes), CD14−
CD19− (other) (Supplementary Fig. 5), and percentage live cells expressing cytokine from each of these were plotted. Samples with a frequency of
cytokines below 0.02% of live lymphocytes after removal of background were excluded from this analysis. a IFNγ (n= 13), b IL-4 (n= 9), and c IL-10
(n= 6). Median ± interquartile range is indicated. d Boolean gating for combinations of cytokines shown as percentage of live cells, n= 20. Median ±
interquartile range is indicated. The gating strategy is shown in Supplementary Fig. 5. e Plots were gated on IL-10+CD4+ T cells following negative control
(DMSO) or α-syn stimulation. The gating strategy leading up to this step is shown in Supplementary Fig. 5. IL-10+ cells were then gated further on CD25
and CD127 expression (top row). Plots were gated on CD25+CD127loCD4+ T cells and then on IL-10 production (bottom row).
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PD diagnosis. Among the PD cohorts studied after clinical
diagnosis of motor PD, we further show that T cell reactivity was
positively correlated with age and inversely correlated with LED,
but did not correlate with motor and cognitive impairment.
The case study of an individual for which PBMC samples were
independently obtained and stored over a 20-year period both
before and after clinical diagnosis of motor PD provides a unique
opportunity to examine PD disease progression. We found that α-
syn-specific T cell reactivity was present before onset of motor
symptoms and clinical diagnosis of PD and then declined after.
The observation that α-syn reactivity was present during the
preclinical phase is compatible with a causal relationship between
T cell-mediated inflammation and PD disease. Replication of
these findings in larger population-based longitudinal studies will
be important, but such cohorts are currently not available.
Notably, the case study subject reported having shingles ~1–2
years before PD diagnosis, and we detected a wide variation in
α-syn-specific T cell reactivity in samples during that period. It is
unclear whether these variations may be due to variations in
sample quality and/or the limited number of cells, which did not
allow a repeat of the assay multiple times as for other time points.
The variation may also be explained by the shingles episode
affecting the α-syn-specific T cell responses. This observation is
intriguing in the context of a putative role of viral infections in
PD pathogenesis15,16. We speculate that the variability in T cell
reactivity may have initiated spreading of inflammation and
immune responses in the brain that later could not be controlled.
Prompted by these observations, we examined the relation
between time from diagnosis of motor PD and α-syn-specific
T cell reactivity in two independent cohorts of PD patients and
found a significant relationship between time from diagnosis and
reactivity. The correlation between α-syn-specific T cell reactivity
and time from diagnosis also suggests a pathogenic role of T cell
reactivity, but it will be important to examine this further in
preclinical and prodromal cohorts, as the mechanism is currently
not understood. There is a potential for epitope spreading to
occur over time. Due to the limited number of cells, we were
unable to identify individual epitopes in all subjects. The limited
a b
c d e
f g h
Fig. 6 Correlation between α-syn-specific T cell reactivity and clinical variables. a Age (n= 97): dotted lines indicate 250 SFC and 70-year-old cut-off
for two-tailed Fisher’s exact test. b Frequency and magnitude of T cell responses in males (n= 71) and females (n= 26) with PD. The dotted line indicates
250 SFC for Fisher’s exact test. c MoCA score (n= 85), d UPDRS score (n= 85), and e LED score (n= 86); dotted lines indicate 250 SFC and 1000 LED
cut-off for two-tailed Fisher’s exact test. f Correlation between LED score and time since diagnosis (n= 86); dotted lines indicate 10 years since diagnosis
and 1000 LED cut-off for two-tailed Fisher’s exact test. Correlation is indicated by Spearman r and associated p value. g Segregation of subjects with PD in
low (<1000) and high (≥1000) LED score with diagnosis <10 and ≥10 years ago. Number of data points per condition is indicated in the figure (Total No.).
Two-tailed Fisher’s exact test comparing individuals with <1000 LED, <10 years ago since diagnosis and >250 SFC (left in graph) vs. the three other groups.
h Segregation of subjects with PD based on LED score (cut-off 1000), years since diagnosis (cut-off 10) and age (cut-off 70). Two-tailed Fisher’s exact test
comparing individuals with <1000 LED, <10 years ago since diagnosis, >70 years old, and >250 SFC (left in graph) vs. the seven other groups. Total
number of PD responding to α-syn peptide pool (n= 28). Total SFC is defined as the magnitude of responses (sum of IFNγ, IL-5, and IL-10) against the
α-syn peptide pool as SFC per 106 cultured PBMC. b, g, h Median ± interquartile range is indicated.
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data in the case study suggests that there was no epitope
spreading, as the epitope specificity remained constant between
2005 and 2015.
The studies in these cohorts also suggested a role for cytokine-
producing α-syn-specific T cells in PD progression. It is well
known that T cells are very heterogeneous17, with different sub-
sets functionally distinguished on the basis of differential cytokine
secretion. While IFNγ and IL-4/5 secretion are associated with
typical inflammatory Th1/Th1* and Th2 subsets18, other cyto-
kines such as IL-10 that have anti-inflammatory activity are
associated with several different subsets, including Tregs, Tr1, and
others19.
In this study, we compared α-syn-specific T cell responses
between PD patients and age-matched HC. One limitation to this
study is that, while the sample size is relatively large, the PD
patients and HC were unbalanced for sex. No difference in α-syn-
specific T cell reactivity was found between individuals diagnosed
with AD and age-matched HC. Comparison of α-syn-specific T
cell reactivity to additional neurodegenerative diseases will reveal
whether the reactivity is a marker of neuronal loss and associated
neuroinflammation that may occur in multiple neurodegenerative
diseases, rather than being specific to PD.
Here, we measured classical inflammatory cytokines as well
as IL-10. Significant amounts of IL-10 were produced in addi-
tion to IFNγ and IL-5. The IL-10 production suggests the
possibility that these cells correspond to a compensatory and
regulatory subset. Our limited analysis to date indicates that
they are T cells that do not express typical markers of the Treg
lineage and are distinct from those producing inflammatory
cytokines. These cells might correspond to a specific T cell
subset that can be characterized further in future studies. Their
isolation and characterization could pave the way for active or
passive immunotherapy of PD20–22.
We also examined the correlation between the presence of
different HLA types and PD status (comparing PD with non-PD
controls) and in parallel examined the correlation between HLA
type and α-syn-specific reactivity in both HC and PD. No sig-
nificant association was detected when Bonferroni corrections
were applied. Thus, the current analysis does not confirm the
previous trend (not Bonferroni corrected) for an association with
HLA DRB1*15:01 and DRB5*01:019. It should be noted that the
previous analysis was performed with a specific DRB1*15:01/
DRB5*01:01 restricted epitope, whereas here we studied a pool of
11 α-syn epitopes. In addition, the previous analysis was per-
formed with subjects essentially from a single site, while the
present analysis included a more diverse geographical and ethnic
basis (New York, Chicago, San Diego, and Birmingham). We also
did not find any significant HLA association (Bonferroni cor-
rected) when the individuals from all sites (previous analysis and
the current cohorts) were analyzed together. In addition, we did
not detect a significant association with the “shared haplotype”
recently reported in association with PD23. The present study
included a total of 164 subjects and was therefore associated with
higher statistical power. We conclude that the issue of HLA
association with PD should be addressed in further studies with a
larger number of subjects analyzed. We are also currently in the
process of coupling HLA association studies with TCR repertoire
analyses.
Having established a correlation with time since diagnosis, we
focused on additional variables of clinical significance. We
detected a trend for association of T cell responses and sex,
consistent with the bias of disease occurrence in males24. We also
detected a correlation with reactivity and age, with responses
tending to increase with age in the individuals with PD, but not
the HC. It is important to emphasize that the α-syn-specific
reactivity decreases as a function of time from diagnosis but
increases as a function of age. This observation excludes a general
reduction in reactivity due to aging and is more compatible with a
general increase in propensity to autoimmunity with increased
age as has been previously described14,25. Surprisingly, we did not
detect significant correlation or association with cognitive func-
tion (MoCA) or motor (UPDRS) scores. We propose that this
might be reflective of the T cell reactivity largely preceding the
clinical stage as in classical autoimmune diseases26–28, and of T
cell reactivity mediating the damage, which does not correlate
with disease severity that appears after most of the damage has
occurred.
Our analysis detected a strong correlation with low LED
(medication scores), and that, while time from diagnosis is as
expected correlated with low LED, the two variables also act
synergistically. While patients with both low LED and a recent
diagnosis exhibit high α-syn-specific reactivity, patients with low
LED/distant diagnosis or high LED/recent diagnosis do not show
the same high reactivity. This explanation is puzzling, and might
relate to high LED/recent diagnosis as a different disease phe-
notype, with accelerated pathogenesis requiring more medication,
or donors where time since diagnosis does not accurately reflect
disease onset. One caveat to this study is the risk of potential
misdiagnosis of PD in early disease; our PD cohorts were enrolled
by fellowship-trained movement disorder specialists and previous
studies have shown that the rate of incorrect diagnosis in early PD
is around 15%29,30. This could also be addressed in a future
longitudinal study.
By combining the three variables (age, LED, and time from
diagnosis), we achieved the best classification of PD α-syn
responders, with almost 70% specificity but low (54%) sensitivity,
perhaps because the reactivity of additional antigens in addition
to α-syn might be involved in PD pathogenesis. This is consistent
with recent reports of reactivity against tau, β-synuclein, and
hypocretin31–33. The sensitivity could likely be improved by
including additional antigens involved in PD pathogenesis, as well
as by narrowing the window of time since onset of disease for a
diagnostic application. In terms of specificity, it is possible that
some of the age-matched controls will eventually develop PD,
considering that reactivity in the case study was detected long
before diagnosis.
In conclusion, the present study confirms an association of α-
syn-specific T cells and PD, and demonstrates that the presence of
these T cells is a feature of preclinical and early motor PD. These
observations also suggest that the monitoring α-syn-specific T cell
reactivity of at-risk populations, such as REM sleep behavior
disorder patients and LRRK2 or GBA carriers, might provide a
strategy to identify individuals for preventive treatments and
immunotherapy approaches. The feasibility of such an approach
is reinforced by a recent report that patients undergoing anti-TNF
treatments are associated with lower incidence of PD34.
Methods
Study approval. All participants provided written informed consent for partici-
pation in the study. In the case of the AD cohort, all the participants or their
authorized representatives provided written informed consent. Ethical approval
was obtained from the institutional review boards at La Jolla Institute for Immu-
nology (LJI; Protocol Nos VD-167, VD-124, VD-118, VD-155, and VD-187), Rush
University Medical Center (RUMC; Office of Research Affairs No. 16042107-
IRB01), University of California San Diego (UCSD; Protocol No. 161224), Uni-
versity of Alabama (UAB; Protocol No. IRB-300001297) and Columbia University
Medical Center (CUMC; Protocol No. IRB-AAAQ9714).
Study subjects' PD and age-matched HC. We recruited a total of 97 parti-
cipants with PD and 67 age-matched healthy controls without PD from the
greater San Diego (PD, n= 44; 11 LJI, 33 UCSD; HC, n= 35 from UCSD), Chicago
(PD, n= 31; HC, n= 32), and Birmingham, Alabama (PD, n= 22, where 20 were
used as an independent validation cohort; HC, n= 0) areas; cross-sectional cohort
characteristics are shown in Table 2. Blood samples were collected by trained staff.
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The San Diego cohort was recruited by the clinical core at LJI and by the
Department of Neurology at UCSD. The Alabama cohort was recruited from the
clinical practice of the UAB Movement Disorders Clinic and the Chicago cohort
was recruited from the Rush Parkinson’s Disease and Movement Disorders Pro-
gram. PD participants were enrolled on the basis of the following inclusion criteria:
moderate to advanced PD; 2 of: rest tremor, rigidity, and/or bradykinesia, PD
diagnosis at age 45–75, dopaminergic medication benefit, and ability to provide
informed consent, by fellowship-trained movement disorder specialists. Early
diagnosis was defined as <10 years prior to sample donation. The exclusion criteria
were atypical parkinsonism or other neurological disorders, history of cancer
within the past 3 years (not skin), autoimmune disease (except thyroid), and
chronic immune-modulatory therapy. Age-matched HC were selected on the basis
of age 48–90 and ability to provide informed consent. Exclusion criteria were the
same as for PD donors, and, in addition, we excluded self-reported genetic factors
(i.e., PD in first-degree blood relative). In the LJI cohort, PD was self-reported. The
PD individuals recruited at RUMC, UAB, and UCSD all fulfilled the UK Parkin-
son’s Disease Society Brain Bank criteria for PD. For the PD patients, the median
age at diagnosis was 58 years.
The case study experienced onset of symptoms in 2008 and was diagnosed with
PD in 2009 when he was 47 years old. He had an episode of shingles in 2007. Upon
diagnosis, the case study, a right-hand-dominated man, presented with a year's
history of tremors involving the left arm. He also complained of a sore feeling in the
arm and some problems while running involving his left leg. There was a family
history of essential tremor, but no history of sleeping problems. He denied having
constipation or anosmia, and there was no micrographia. Examination revealed a
healthy-appearing male who was cognitively intact (mini-mental state examination
(MMSE)—30). He had classic intermittent resting tremor involving the left arm,
mild to moderate left arm rigidity, and mild slowing of finger tapping on the left. He
had diminished left arm swing, but gait was otherwise normal with a UPDRS motor
score of 9. He had a Hoehn & Yahr score Stage 1. He started rasagaline 1 month
after first the evaluation in 2009. He started Levodopa in December 2015 and had
implantation of bilateral subthalamic stimulators in June 2017 due to intractable
tremors. Cryopreserved PBMCs derived from either whole blood or leukapheresis
donations, isolated using Ficoll-PaqueTM density-gradient centrifugation as below,
were provided from various time points between 1998 and 2018.
Study subjects' AD and age-matched HC. We recruited a total of 38 participants
with AD and 41 age-matched healthy controls without AD from the Alzheimer’s
Disease Research Center at CUMC (AD, n= 20; HC, n= 21) and Precision Med a
Contract Research Organization (AD, n= 18; HC, n= 20). Demographic char-
acteristics of AD and matched HC are listed in Table 3. Blood samples were
collected by trained staff.
Subjects from CUMC were diagnosed by neurologists according to the National
Institute of Aging and Alzheimer’s Association criteria35. All AD subjects were
probable AD, recruited after at least two clinical visits. Ten AD individuals had
neuropsychological testing only; the remaining 10 had neuropsychological testing and
positive biomarkers (SPECT scan, FDG PET scan, CSF, or amyloid scan). Twenty-one
HC were recruited from the Alzheimer’s Disease Research Center at Columbia
University. Assessments entail annual neurological and neuropsychological testing
(Unified Data Set 3). They were evaluated for at least 2 consecutive years with a
normal neuropsychological testing. The neuropsychological testing includes MMSE,
MoCA, digit forward and backward, trail making A and B, fluency (phonemic and
semantic), multilingual naming test, logical memory (CRAFT), selective reminding
test, Benson complex figure (copy and recall), and Rosen, as well as global deficit score
and Neuropsychiatric Inventory questionnaire. Five HC were recruited based on a
negative amyloid scan and a more limited neuropsychological testing.
The AD cohort recruited by Precision Med were diagnosed according to the
National Institute of Neurological and Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related Disorders Association criteria36 by a
neurologist or internist. In addition, the subjects underwent MRI/CT scans to rule
out other causes of cognitive decline. Their MMSE score is ≤28. They exhibit
deficits in two or more areas of cognition and have progressive worsening of
memory and other cognitive functions including progressive deterioration of
specific cognitive functions such as language (aphasia), motor skills (apraxia), and
perceptions (agnosia). The diagnosis is further supported by impaired activities of
daily living, altered patterns of behavior, and family history of similar disorders.
The HC are self-reported without evidence for decline in cognitive functions. The
HC have an MMSE of ≥29.
Peptides. Peptides were synthesized by A&A, LLC (San Diego, CA) as purified
material (>95% by reverse-phase HPLC). Peptides were fifteen 15-mers previously
described as T cell epitopes9, which were combined into two α-syn peptide pools,
one for the case study (n= 12) and one for the cross-sectional study (n= 11;
Supplementary Table 2). Peptides were aliquoted in small volumes and stored at
−20 °C to avoid multiple freeze–thaw cycles.
PBMC isolation and in vitro expansion. Venous blood was collected in antic-
oagulant (e.g., heparin or EDTA)-containing blood bags or tubes. PBMC were
purified from whole blood using Ficoll-PaqueTM density-gradient centrifugation,
according to the manufacturer’s instructions (GE Healthcare Bio-Sciences, Pitts-
burgh, PA). Cells were cryopreserved in liquid nitrogen suspended in FBS con-
taining 10% (vol/vol) DMSO. For in vitro expansion, cryopreserved PBMCs were
thawed in RPMI supplemented with 5% human serum (Gemini Bio-Products,
West Sacramento, CA), 1% Glutamax (Gibco, Waltham, MA), 1% penicillin/
streptomycin (Omega Scientific, Tarzana, CA), and 50 U/ml Benzonase (Millipore
Sigma, Burlington, MA). The cells were then washed and viability was evaluated
using the trypan blue dye exclusion method. Briefly, at a density of 2 × 106 per mL,
the cells were plated in each well of a 24-well plate in the presence of a α-syn
peptide pool at a concentration of 5 μg/ml and were incubated in a 37 °C humi-
dified CO2 incubator for 2 weeks. Intermittently, every 3 days, cells were supplied
with 10 U/ml recombinant human IL-2.
Fluorospot assay. After 14 days of culture with α-synuclein peptide pool (5 μg/ml),
α-synuclein-specific cellular responses were measured by IFNγ, IL-5, and IL-10
Fluorospot assay with all antibodies and reagents from Mabtech (Nacka Strand,
Sweden). Plates were coated overnight at 4 °C with an antibody mixture containing
mouse anti-human IFNγ (clone 1-D1K), mouse anti-human IL-5 (clone TRFK5),
and mouse anti-human IL-10 (clone 9D7). Briefly, 1 × 105 cells were added to each
well of pre-coated Immobilon-FL PVDF 96-well plates (Mabtech) in the presence
of a 5 μg/ml peptide pool and incubated at 37 °C in a humidified CO2 incubator for
20–24 h. Cells from the in vitro culture stimulated with DMSO (corresponding to
the percent DMSO in the peptide pool tests) were used to assess nonspecific/
background cytokine production and PHA stimulation at 10 μg/ml was used as a
positive control. All conditions were tested in triplicate. Fluorospot plates were
developed according to the manufacturer’s instructions (Mabtech). Briefly, cells
were removed and plates were washed six times with 200 μl PBS/0.05% Tween 20
using an automated plate washer. After washing, 100 μl antibody mixture con-
taining IFNγ (7-B6-1-FS-BAM), IL-5 (5A10-WASP), and IL-10 (12G8-biotin)
prepared in PBS with 0.1% BSA was added to each well and the plates were
incubated for 2 h. The plates were again washed six times with 200 μl PBS/0.05%
Tween 20 using an automated plate washer and incubated with diluted fluor-
ophores (anti-BAM-490, anti-WASP-640, and SA-550) for 1 h at room tempera-
ture. Finally, the plates were once more washed six times with 200 μl PBS/0.05%
Tween 20 using an automated plate washer and incubated with a fluorescence
enhancer for 15 min at room temperature. The plates were blotted dry and spots
Table 2 Demographic characteristics of enrolled PD and
matched HC.
Characteristics PD HC
Total participants enrolled, n 97 67
Median age (range), years 67 (45–87) 64 (48–83)
Male, % (n) 73 (71) 25 (17)
Caucasian, % (n) 86 (83) 84 (56)
Median age at diagnosis
of PD, (range), years
58 (37–80) N/A
Median years since diagnosis,
(range), years
6 (0–27) N/A
Median UPDRS Part IIIa (range) 23 (1–47) N/A
Median MoCAb (range) 26 (13–30) 26 (18–31)
Median LEDc (range) 520 (0–2300) N/A
aUPDRS Part III collected at RUMC, UAB, and UCSD.
bMoCA collected at RUMC (PD and HC), UAB (PD only), and UCSD (PD only).
cLED collected at RUMC, UAB, and UCSD.
Table 3 Demographic characteristics of enrolled AD and
matched HC.
Characteristics AD HC
Total participants enrolled, n 38 41
Median age (range), years 69 (52–89) 66 (56–92)
Male, % (n) 47 (18) 46 (19)
Caucasian, % (n) 53 (20) 90 (37)
Median age at diagnosis of AD,
(range), years
63 (47–84) N/A
Median years since diagnosis, (range), years 4 (0.5–11) N/A
Median MMSEa (range) 22 (16–28) N/A
Median MoCAb (range) 20 (7–26) 26 (18–31)
aMMSE collected by Precision Med only.
bMoCA collected at CUMC only.
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were counted by computer-assisted image analysis (AID iSpot, Aid Diagnostica
GMBH, Strassberg, Germany). Responses were considered positive if the net
spot-forming cells (SFC) per 106 PBMC were ≥100, the stimulation index ≥2, and
p ≤ 0.05 by Student’s t test or Poisson distribution test.
Intracellular cytokine staining (ICS). After 14 days of culture, an intracellular
cytokine staining (ICS) assay was performed by stimulating PBMCs with 5 μg/ml
α-synuclein epitope pool for 2 h in complete RPMI medium at 37 °C. After 2 h,
brefeldin A and monensin, each at a concentration of 2.5 μg/ml, were added for an
additional 4 h. Cells were incubated for a total of 6 h at 37 °C in humidified CO2
incubator. Stimulated cells were harvested, washed, and stained for cell surface
antigens according to the staining panel used (Supplementary Table 3), and fixable
viability dye eFluor 506 (eBiosciences, Waltham, MA). After 30 min of staining,
cells were washed, fixed using 4% paraformaldehyde and permeabilized using
saponin buffer. Cells were stained for cytokines (Supplementary Table 3) in
saponin buffer containing 10% FBS. Samples were acquired on a BD LSR II flow
cytometer (BD Biosciences, San Jose, CA). Frequencies of CD3+ T cells responding
to α-synuclein epitope pool were quantified by determining the total number of
gated CD3+ and cytokine+ cells and background values subtracted (as determined
from the medium alone control) using FlowJo X Software (FlowJo LLC, Ashland,
OR). Combinations of cytokine producing cells were determined using Boolean
gating. The gating strategy is described in Supplementary Fig. 5.
HLA typing. Participants were HLA typed by an ASHI-accredited laboratory at
Murdoch University (Institute for Immunology & Infectious Diseases, Western
Australia). HLA typing for class I (HLA A; B; C) and class II (DQA1; DQB1, DRB1
3,4,5; DPB1) was performed using locus-specific PCR amplification of genomic DNA.
Primers used for amplification employed patient-specific barcoded primers. Ampli-
fied products were quantitated and pooled by subject, and up to 48 subjects were
pooled. An indexed (eight indexed MiSeq runs) library was then quantitated using
Kappa universal QPCR library quantification kits. Sequencing was performed using
an Illumina MiSeq using 2 × 300 paired-end chemistry. Reads were quality-filtered
and passed through a proprietary allele calling algorithm and analysis pipeline using
the latest IMGT HLA allele database as a reference. The algorithm was developed by
E.P. and S.M. and relies on periodically updated versions of the freely available
international immunogenetics information system (http://www.imgt.org) and an
ASHI-accredited HLA allele caller software pipeline, IIID HLA Analysis suite (http://
www.iiid.com.au/laboratory-testing/). HLA association odds ratios and relative fre-
quencies were calculated using the RATE program37 available from www.iedb.org.
Statistical analyses. Statistical analyses were performed using GraphPad Prism
version 7 (GraphPad Software, San Diego, CA). Data were analyzed using non-
parametric statistical tests (Spearman test) because the data are not normally
distributed. Fisher’s exact t test (two-tailed), which provides exact p values for the
analysis of contingency tables, was calculated using online GraphPad tool Quick-
calcs. Mann–Whitney test (two-tailed) was performed to compare gender-based
distribution of PD and frequency of T cell responses in PD and age-matched
healthy controls. For all analyses, differences were considered significant if the
p value was ≤0.05.
Unless indicated in the figure legend (Fig. 1e, f), each donor sample was
included in one experiment.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in this article and its
Supplementary Information. For HLA-typing information from the freely available
international immunogenetics information system (http://www.imgt.org), and an ASHI-
accredited HLA allele caller software pipeline, IIID HLA Analysis suite (http://www.iiid.
com.au/laboratory-testing/) was used.
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